Bolt Biotherapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
87
- Stock Symbol
-
BOLT
- Share Price
-
$6.10
- (As of Friday Closing)
Bolt Biotherapeutics General Information
Description
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.
Contact Information
Website
www.boltbio.comCorporate Office
- 900 Chesapeake Drive
- Redwood City, CA 94063
- United States
Corporate Office
- 900 Chesapeake Drive
- Redwood City, CA 94063
- United States
Bolt Biotherapeutics Stock Performance
As of 13-Jun-2025, Bolt Biotherapeutics’s stock price is $6.10. Its current market cap is $11.7M with 1.92M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $6.10 | $6.23 | $5.20 - $15.60 | $11.7M | 1.92M | 19.7K | -$33.40 |
Bolt Biotherapeutics Financials Summary
As of 31-Mar-2025, Bolt Biotherapeutics has a trailing 12-month revenue of $3.64M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (6,774) | (15,141) | (56,345) | (98,930) |
| Revenue | 3,638 | 7,690 | 7,876 | 5,729 |
| EBITDA | (66,327) | (66,573) | (74,296) | (88,621) |
| Net Income | (63,347) | (63,118) | (69,197) | (88,098) |
| Total Assets | 85,862 | 99,632 | 159,784 | 227,807 |
| Total Debt | 24,709 | 25,209 | 20,219 | 22,611 |
Bolt Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bolt Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Bolt Biotherapeutics Comparisons
Industry
Financing
Details
Bolt Biotherapeutics Competitors (41)
One of Bolt Biotherapeutics’s 41 competitors is Agenus, a Formerly VC-backed company based in Lexington, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Nkarta Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Lyell Immunopharma | Formerly VC-backed | South San Francisco, CA | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA |
Bolt Biotherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Bolt Biotherapeutics Patents
Bolt Biotherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023216956-A1 | Antibody-conjugated 8-sulfonyl-benzazepine compounds and their uses | Pending | 09-Feb-2022 | ||
| AU-2023216955-A1 | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses | Pending | 09-Feb-2022 | ||
| EP-4475892-A1 | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses | Pending | 09-Feb-2022 | ||
| EP-4475893-A1 | Antibody-conjugated 8-sulfonyl-benzazepine compounds and their uses | Pending | 09-Feb-2022 | ||
| US-20250145575-A1 | Macromolecule-supported 8-sulfonyl-benzazepine compounds and their uses | Pending | 09-Feb-2022 | C07D223/16 |
Bolt Biotherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Bolt Biotherapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bolt Biotherapeutics ESG
Risk Overview
Risk Rating
Updated December, 06, 2022
31.6 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Pharmaceuticals
Subindustry
of 473
Rank
Percentile
Bolt Biotherapeutics FAQs
-
When was Bolt Biotherapeutics founded?
Bolt Biotherapeutics was founded in 2015.
-
Where is Bolt Biotherapeutics headquartered?
Bolt Biotherapeutics is headquartered in Redwood City, CA.
-
What is the size of Bolt Biotherapeutics?
Bolt Biotherapeutics has 87 total employees.
-
What industry is Bolt Biotherapeutics in?
Bolt Biotherapeutics’s primary industry is Drug Discovery.
-
Is Bolt Biotherapeutics a private or public company?
Bolt Biotherapeutics is a Public company.
-
What is Bolt Biotherapeutics’s stock symbol?
The ticker symbol for Bolt Biotherapeutics is BOLT.
-
What is the current stock price of Bolt Biotherapeutics?
As of 13-Jun-2025 the stock price of Bolt Biotherapeutics is $6.10.
-
What is the current market cap of Bolt Biotherapeutics?
The current market capitalization of Bolt Biotherapeutics is $11.7M.
-
What is Bolt Biotherapeutics’s current revenue?
The trailing twelve month revenue for Bolt Biotherapeutics is $3.64M.
-
Who are Bolt Biotherapeutics’s competitors?
Agenus, CytomX Therapeutics, Nkarta Therapeutics, Lyell Immunopharma, and Sorrento Therapeutics are some of the 41 competitors of Bolt Biotherapeutics.
-
What is Bolt Biotherapeutics’s annual earnings per share (EPS)?
Bolt Biotherapeutics’s EPS for 12 months was -$33.40.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
